A Phase 2 interventional study of Mirikizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 40 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-18.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 15th largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 2, and was the 17th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
Drug: Mirikizumab
100 mg Mirikizumab administered SC Q8W.
Drug: Mirikizumab
300 mg Mirikizumab administered SC Q8W.
Drug: Mirikizumab
Placebo administered SC Q8W.
Drug: Placebo
Administered SC
Also known as: LY3074828
Administered SC
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Time frame: Week 16
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Time frame: Week 16
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Time frame: Week 16
Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1
The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.
Time frame: Week 16
Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score
PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region \[United States/Outside United States (US/OUS)\], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.
Time frame: Baseline, Week 16
Mean Change (Improvement) From Baseline on the Patient Global Assessment
The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.
Time frame: Baseline, Week 16
Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score
The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.
Time frame: Baseline, Week 16
Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.
Time frame: Baseline, Week 16
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104
Time frame: Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 52, Week 56, Week 64, Week 72, Week 80, Week 88, Week 96, Week 100, Week 104
| Milestone | Induction: Placebo | Induction: 30 mg Mirikizumab Q8W | Induction:100 mg Mirikizumab Q8W | Induction: 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Maintenance: Placebo to 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | Maintenance: 300 mg Mirikizumab Q8W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 52 | 51 | 51 | 51 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 52 | 51 | 51 | 51 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 50 | 49 | 51 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction: Placebo | Induction: 30 mg Mirikizumab Q8W | Induction:100 mg Mirikizumab Q8W | Induction: 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Maintenance: Placebo to 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | Maintenance: 300 mg Mirikizumab Q8W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 15 | 30 | 34 | 50 | 34 | 21 | 15 |
| Rescue participants | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Roll over to amah (nct03556202) | 0 | 0 | 0 | 13 | 9 | 18 | 26 | 42 | 24 | 17 | 0 |
| Completed | 0 | 0 | 0 | 0 | 13 | 27 | 30 | 45 | 30 | 19 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 5 | 4 | 2 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 2 | 2 | 0 | 1 |
| Milestone | Induction: Placebo | Induction: 30 mg Mirikizumab Q8W | Induction:100 mg Mirikizumab Q8W | Induction: 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Maintenance: Placebo to 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | Maintenance: 300 mg Mirikizumab Q8W |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 3 | 6 | 2 | 0 |
| Completed | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 3 | 6 | 2 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
| percentage of participants | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) | 0 (0 to 0) | 29.4 (16.9 to 41.9) | 58.8 (45.3 to 72.3) | 66.7 (53.7 to 79.6) |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
| percentage of participants | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) | 0 (0 to 0) | 15.7 (5.7 to 25.7) | 31.4 (18.6 to 44.1) | 31.4 (18.6 to 44.1) |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
| percentage of participants | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) | 3.8 (0 to 9.1) | 52.9 (39.2 to 66.6) | 78.4 (67.1 to 89.7) | 74.5 (62.5 to 86.5) |
The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.
| percentage of participants | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| sPGA (0) | 0 (0 to 0) | 15.7 (5.7 to 25.7) | 31.4 (18.6 to 44.1) | 31.4 (18.6 to 44.1) |
| sPGA (0/1) | 1.9 (0 to 5.7) | 37.3 (24.0 to 50.5) | 70.6 (58.1 to 83.1) | 68.6 (55.9 to 81.4) |
PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region \[United States/Outside United States (US/OUS)\], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.
| units on a scale | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score | -4.35 ± 2.29 | -31.19 ± 2.34 | -42.33 ± 2.37 | -33.66 ± 2.27 |
The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.
| units on a scale | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Mean Change (Improvement) From Baseline on the Patient Global Assessment | 0.35 ± 0.16 | 2.24 ± 0.16 | 2.91 ± 0.16 | 2.82 ± 0.16 |
The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". For all questions, if unanswered the question is scored as "0". Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.
| score on a scale | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score | -1.07 ± 0.69 | -9.19 ± 0.71 | -10.18 ± 0.69 | -9.64 ± 0.70 |
The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.
| score on a scale | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab |
|---|---|---|---|---|
| MCS | 0.28 ± 0.87 | 2.39 ± 0.90 | 2.74 ± 0.88 | 1.52 ± 0.88 |
| PCS | 1.23 ± 0.84 | 4.58 ± 0.88 | 4.40 ± 0.85 | 5.09 ± 0.85 |
Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104
| nanogram*hour per milliliter (ng*hr/mL) | 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Placebo to 300 mg Mirikizumab Q8W | 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | 300 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W |
|---|---|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104 | 3.22 ± 46.33 | 8.94 ± 79.19 | 22.96 ± 55.80 | 46.4 ± 62.8 | 34.83 ± 92.13 | 47.66 ± 70.08 | 51.30 ± 43.54 |
Collected over Up To 120 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction: Placebo | 0/52 (0%) | 1/52 (1.9%) | 19/52 (36.5%) |
| Induction: 30 mg Mirikizumab Q8W | 0/51 (0%) | 1/51 (2%) | 24/51 (47.1%) |
| Induction:100 mg Mirikizumab Q8W | 0/51 (0%) | 0/51 (0%) | 19/51 (37.3%) |
| Induction: 300 mg Mirikizumab Q8W | 0/51 (0%) | 1/51 (2%) | 19/51 (37.3%) |
| Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | 0/15 (0%) | 1/15 (6.7%) | 13/15 (86.7%) |
| Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | 0/30 (0%) | 2/30 (6.7%) | 20/30 (66.7%) |
| Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | 0/34 (0%) | 1/34 (2.9%) | 23/34 (67.6%) |
| Maintenance: Placebo to 300 mg Mirikizumab Q8W | 0/50 (0%) | 2/50 (4%) | 38/50 (76%) |
| Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | 0/34 (0%) | 2/34 (5.9%) | 28/34 (82.4%) |
| Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | 0/21 (0%) | 2/21 (9.5%) | 18/21 (85.7%) |
| Maintenance: 300 mg Mirikizumab Q8W | 0/15 (0%) | 3/15 (20%) | 13/15 (86.7%) |
| 300 mg Mirikizumab Q8W-Rescue | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Placebo to 300 mg Mirikizumab Q8W-Follow-up | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Event | Induction: Placebo | Induction: 30 mg Mirikizumab Q8W | Induction:100 mg Mirikizumab Q8W | Induction: 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Maintenance: Placebo to 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | Maintenance: 300 mg Mirikizumab Q8W | 300 mg Mirikizumab Q8W-Rescue | 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up | 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up | 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up | Placebo to 300 mg Mirikizumab Q8W-Follow-up | 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up | 100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 1/21 | 0/15 | 1/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Atrial fibrillationCardiac disorders | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 0/21 | 1/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| ErysipelasInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 0/21 | 1/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| PneumoniaInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 0/21 | 1/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Cerebral haemorrhageNervous system disorders | 0/52 | 0/51 | 0/51 | 0/51 | 1/15 | 0/30 | 0/34 | 0/50 | 0/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Femur fractureInjury, poisoning and procedural complications | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 1/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Endocarditis bacterialInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 1/30 | 0/34 | 0/50 | 0/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Intraocular melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 1/30 | 0/34 | 0/50 | 0/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Enlarged uvulaGastrointestinal disorders | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 1/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Pyelonephritis acuteInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 1/34 | 0/50 | 0/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Event | Induction: Placebo | Induction: 30 mg Mirikizumab Q8W | Induction:100 mg Mirikizumab Q8W | Induction: 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN | Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN | Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN | Maintenance: Placebo to 300 mg Mirikizumab Q8W | Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W | Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W | Maintenance: 300 mg Mirikizumab Q8W | 300 mg Mirikizumab Q8W-Rescue | 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up | 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up | 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up | Placebo to 300 mg Mirikizumab Q8W-Follow-up | 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up | 100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/52 | 0/51 | 1/51 | 0/51 | 0/15 | 1/30 | 2/34 | 3/50 | 2/34 | 1/21 | 1/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 1/2 |
| NasopharyngitisInfections and infestations | 7/52 | 5/51 | 6/51 | 8/51 | 3/15 | 3/30 | 7/34 | 15/50 | 12/34 | 5/21 | 5/15 | 2/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Skin papillomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 1/30 | 0/34 | 1/50 | 2/34 | 0/21 | 0/15 | 0/10 | 0/2 | 1/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 2/52 | 6/51 | 3/51 | 2/51 | 2/15 | 5/30 | 2/34 | 8/50 | 3/34 | 5/21 | 1/15 | 1/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| HypertensionVascular disorders | 0/52 | 0/51 | 3/51 | 3/51 | 0/15 | 3/30 | 3/34 | 4/50 | 3/34 | 5/21 | 1/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Back painMusculoskeletal and connective tissue disorders | 1/52 | 1/51 | 1/51 | 0/51 | 1/15 | 1/30 | 0/34 | 3/50 | 8/34 | 3/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Injection site painGeneral disorders | 1/52 | 3/51 | 3/51 | 2/51 | 1/15 | 1/30 | 1/34 | 4/50 | 3/34 | 2/21 | 0/15 | 2/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| BronchitisInfections and infestations | 1/52 | 1/51 | 1/51 | 0/51 | 0/15 | 1/30 | 0/34 | 0/50 | 1/34 | 2/21 | 3/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 0/6 | 0/2 |
| Ear infectionInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 0/50 | 0/34 | 0/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 1/6 | 0/2 |
| PneumoniaInfections and infestations | 0/52 | 0/51 | 0/51 | 0/51 | 0/15 | 0/30 | 0/34 | 1/50 | 0/34 | 1/21 | 0/15 | 0/10 | 0/2 | 0/4 | 0/3 | 0/3 | 1/6 | 0/2 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab | Total |
|---|---|---|---|---|---|
| Mean | 46.0 ± 12.39 | 49.2 ± 13.28 | 46.0 ± 13.18 | 47.5 ± 13.23 | 47.2 ± 12.99 |
| Sex: Female, Male(Participants) | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab | Total |
|---|---|---|---|---|---|
| Female | 10 | 12 | 16 | 15 | 53 |
| Male | 42 | 39 | 35 | 36 | 152 |
| Ethnicity (NIH/OMB)(Participants) | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 7 | 4 | 5 | 24 |
| Not Hispanic or Latino | 39 | 37 | 42 | 42 | 160 |
| Unknown or Not Reported | 5 | 7 | 5 | 4 | 21 |
| Race (NIH/OMB)(Participants) | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 7 | 7 | 6 | 26 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 3 | 3 | 8 |
| White | 44 | 43 | 41 | 42 | 170 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Induction: Placebo | Induction: 30 mg Mirikizumab | Induction: 100 mg Mirikizumab | Induction: 300 mg Mirikizumab | Total |
|---|---|---|---|---|---|
| Canada | 4 | 7 | 7 | 5 | 23 |
| United States | 21 | 20 | 18 | 23 | 82 |
| Japan | 4 | 7 | 5 | 4 | 20 |
| Poland | 19 | 14 | 18 | 14 | 65 |
| Germany | 4 | 3 | 3 | 5 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2016 to primary completion in Jun 2017, 9 months.
Results were first posted in Jun 2020, 2 years 11 months after primary completion. A results delay was requested in Jun 2018.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 9 months is below that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab